MA33197B1 - Inhibiteurs de tripeptide époxy cétone protéases cristallines - Google Patents
Inhibiteurs de tripeptide époxy cétone protéases cristallinesInfo
- Publication number
- MA33197B1 MA33197B1 MA34254A MA34254A MA33197B1 MA 33197 B1 MA33197 B1 MA 33197B1 MA 34254 A MA34254 A MA 34254A MA 34254 A MA34254 A MA 34254A MA 33197 B1 MA33197 B1 MA 33197B1
- Authority
- MA
- Morocco
- Prior art keywords
- epoxy ketone
- tripeptide inhibitors
- protease
- crystalline
- crystalline protease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
- C07K1/026—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution by fragment condensation in solution
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
Abstract
L'invention porte sur des composés tripeptide céto époxyde cristallins, sur leurs procédés de préparation et sur des compositions pharmaceutiques apparentées.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16219609P | 2009-03-20 | 2009-03-20 | |
US18056109P | 2009-05-22 | 2009-05-22 | |
PCT/US2010/028126 WO2010108172A1 (fr) | 2009-03-20 | 2010-03-22 | Inhibiteurs de tripeptide époxy cétone protéases cristallines |
Publications (1)
Publication Number | Publication Date |
---|---|
MA33197B1 true MA33197B1 (fr) | 2012-04-02 |
Family
ID=42738216
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA34254A MA33197B1 (fr) | 2009-03-20 | 2010-03-22 | Inhibiteurs de tripeptide époxy cétone protéases cristallines |
Country Status (45)
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ595196A (en) | 2005-11-09 | 2013-03-28 | Proteolix Inc | Peptide-based compounds for enzyme inhibition |
PL2041158T3 (pl) | 2006-06-19 | 2013-08-30 | Onyx Therapeutics Inc | Peptydowe epoksyketony do hamowania proteasomu |
PL2207791T5 (pl) | 2007-10-04 | 2020-07-27 | Onyx Therapeutics, Inc. | Krystaliczne peptydo- epoksy ketonowe inhibitory proteazy i synteza keto-epoksydów Aminokwasowych |
AP2011005690A0 (en) | 2008-10-21 | 2011-06-30 | Onyx Therapeutics Inc | Combination therapy with peptide epoxyketones. |
TWI504598B (zh) | 2009-03-20 | 2015-10-21 | Onyx Therapeutics Inc | 結晶性三肽環氧酮蛋白酶抑制劑 |
PT3153020T (pt) | 2009-10-07 | 2019-02-26 | Dow Agrosciences Llc | Misturas fungicidas sinérgicas para o controlo de fungos em cereais |
JP5919196B2 (ja) | 2009-11-13 | 2016-05-18 | オニキス セラピューティクス, インク.Onyx Therapeutics, Inc. | 転移抑制のためのペプチドエポキシケトンの使用 |
BR112012022060A2 (pt) | 2010-03-01 | 2018-05-08 | Onyx Therapeutics Inc | composto para a inibição de imunoproteassoma |
NZ602872A (en) | 2010-04-07 | 2014-05-30 | Onyx Therapeutics Inc | Crystalline peptide epoxyketone immunoproteasome inhibitor |
JP2015524394A (ja) | 2012-07-09 | 2015-08-24 | オニキス セラピューティクス, インク.Onyx Therapeutics, Inc. | ペプチドエポキシケトンプロテアーゼ阻害剤のプロドラッグ |
WO2014025023A1 (fr) * | 2012-08-10 | 2014-02-13 | 味の素株式会社 | PROCÉDÉ DE PRODUCTION D'UN CRISTAL DE γ-GLUTAMYL-VALYL-GLYCINE |
TW201422255A (zh) * | 2012-10-24 | 2014-06-16 | Onyx Therapeutics Inc | 用於蛋白酶體抑制劑之調整釋放製劑 |
RU2650402C2 (ru) | 2012-12-28 | 2018-04-11 | ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи | Синергические фунгицидные смеси для борьбы с грибковыми болезнями злаков |
WO2015100184A1 (fr) | 2013-12-26 | 2015-07-02 | Dow Agrosciences Llc | Utilisation de picolinamides macrocycliques en tant que fongicides |
CN104945470B (zh) * | 2014-03-30 | 2020-08-11 | 浙江大学 | 杂环构建的三肽环氧酮类化合物及制备和应用 |
CN104974221B (zh) * | 2014-04-03 | 2020-10-23 | 中国医学科学院药物研究所 | 二肽及三肽类蛋白酶体抑制剂及其制法和药物用途 |
CN106470982A (zh) | 2014-07-08 | 2017-03-01 | 美国陶氏益农公司 | 作为杀真菌剂的大环吡啶酰胺 |
US20160115198A1 (en) | 2014-10-27 | 2016-04-28 | Apicore Us Llc | Methods of making carfilzomib and intermediates thereof |
KR20170100550A (ko) | 2014-12-30 | 2017-09-04 | 다우 아그로사이언시즈 엘엘씨 | 살진균 활성을 갖는 피콜린아미드 화합물 |
CA2972034A1 (fr) | 2014-12-30 | 2016-07-07 | Dow Agrosciences Llc | Picolinamides presentant une activite fongicide |
RU2686987C2 (ru) | 2014-12-30 | 2019-05-06 | ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи | Пиколинамиды в качестве фунгицидов |
US10188109B2 (en) | 2014-12-30 | 2019-01-29 | Dow Agrosciences Llc | Picolinamide compounds with fungicidal activity |
JP6684810B2 (ja) | 2014-12-30 | 2020-04-22 | ダウ アグロサイエンシィズ エルエルシー | 殺真菌剤としてのピコリンアミド化合物の使用 |
CN105949279A (zh) * | 2016-04-27 | 2016-09-21 | 浙江大学 | 蛋白酶体抑制剂Oprozomib及其类似物的制备方法 |
PL3478670T3 (pl) | 2016-06-29 | 2023-07-24 | Kezar Life Sciences | Krystaliczne sole peptydowego epoksyketonowego inhibitora immunoproteasomu |
MX2018016386A (es) | 2016-06-29 | 2019-09-09 | Kezar Life Sciences | Proceso de preparacion de un inhibidor de inmunoproteasoma de peptido epoxicetona, y precursores del mismo. |
US10173982B2 (en) | 2016-08-30 | 2019-01-08 | Dow Agrosciences Llc | Picolinamides as fungicides |
WO2018044991A1 (fr) | 2016-08-30 | 2018-03-08 | Dow Agrosciences Llc | Composés de thiopicolinamide à activité fongicide |
US10111432B2 (en) | 2016-08-30 | 2018-10-30 | Dow Agrosciences Llc | Picolinamide N-oxide compounds with fungicidal activity |
US10034477B2 (en) | 2016-08-30 | 2018-07-31 | Dow Agrosciences Llc | Pyrido-1,3-oxazine-2,4-dione compounds with fungicidal activity |
JP2019529458A (ja) | 2016-09-21 | 2019-10-17 | 小野薬品工業株式会社 | オプロゾミブ用の即放性製剤 |
US20180161279A1 (en) | 2016-12-14 | 2018-06-14 | Amgen Inc. | Gastro-retentive modified release dosage forms for oprozomib and process to make thereof |
BR102018000183B1 (pt) | 2017-01-05 | 2023-04-25 | Dow Agrosciences Llc | Picolinamidas, composição para controle de um patógeno fúngico, e método para controle e prevenção de um ataque por fungos em uma planta |
WO2018204438A1 (fr) | 2017-05-02 | 2018-11-08 | Dow Agrosciences Llc | Utilisation d'un composé picolinamide acyclique en tant que fongicide pour lutter contre des maladies fongiques sur des gazons |
TW201842851A (zh) | 2017-05-02 | 2018-12-16 | 美商陶氏農業科學公司 | 用於穀類中的真菌防治之協同性混合物 |
TWI774761B (zh) | 2017-05-02 | 2022-08-21 | 美商科迪華農業科技有限責任公司 | 用於穀物中的真菌防治之協同性混合物 |
JP2020533382A (ja) | 2017-09-14 | 2020-11-19 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | 癌の組合せ治療 |
BR102019004480B1 (pt) | 2018-03-08 | 2023-03-28 | Dow Agrosciences Llc | Picolinamidas como fungicidas |
KR20210076072A (ko) | 2018-10-15 | 2021-06-23 | 코르테바 애그리사이언스 엘엘씨 | 옥시피콜린아미드의 합성 방법 |
WO2024140736A1 (fr) * | 2022-12-27 | 2024-07-04 | 上海美悦生物科技发展有限公司 | Composé tripeptide époxy cétone, composition pharmaceutique, son procédé de préparation et son utilisation |
Family Cites Families (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4733665C2 (en) | 1985-11-07 | 2002-01-29 | Expandable Grafts Partnership | Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft |
US5135919A (en) | 1988-01-19 | 1992-08-04 | Children's Medical Center Corporation | Method and a pharmaceutical composition for the inhibition of angiogenesis |
US5441944A (en) | 1989-04-23 | 1995-08-15 | The Trustees Of The University Of Pennsylvania | Substituted cyclodextrin sulfates and their uses as growth modulating agents |
US5071957A (en) | 1989-08-04 | 1991-12-10 | Bristol-Myers Company | Antibiotic BU-4061T |
US4990448A (en) | 1989-08-04 | 1991-02-05 | Bristol-Myers Company | Bu-4061T |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
WO1991013904A1 (fr) | 1990-03-05 | 1991-09-19 | Cephalon, Inc. | Proteases analogues a la chymotrypsine et leurs inhibiteurs |
US5561134A (en) * | 1990-09-25 | 1996-10-01 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties |
US5340736A (en) | 1991-05-13 | 1994-08-23 | The President & Fellows Of Harvard College | ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting |
EP0668914B1 (fr) * | 1992-06-09 | 2000-08-16 | Chiron Corporation | Cristallisation du m-csf |
GB9300048D0 (en) | 1993-01-04 | 1993-03-03 | Wellcome Found | Endothelin converting enzyme inhibitors |
TW380137B (en) | 1994-03-04 | 2000-01-21 | Merck & Co Inc | Process for making an epoxide |
US5693617A (en) | 1994-03-15 | 1997-12-02 | Proscript, Inc. | Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein |
US6660268B1 (en) | 1994-03-18 | 2003-12-09 | The President And Fellows Of Harvard College | Proteasome regulation of NF-KB activity |
US6506876B1 (en) | 1994-10-11 | 2003-01-14 | G.D. Searle & Co. | LTA4 hydrolase inhibitor pharmaceutical compositions and methods of use |
US6083903A (en) | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
DE19505263A1 (de) | 1995-02-16 | 1996-08-22 | Consortium Elektrochem Ind | Verfahren zur Reinigung von wasserlöslichen Cyclodextrinderivaten |
US6335358B1 (en) | 1995-04-12 | 2002-01-01 | President And Fellows Of Harvard College | Lactacystin analogs |
US6150415A (en) | 1996-08-13 | 2000-11-21 | The Regents Of The University Of California | Epoxide hydrolase complexes and methods therewith |
WO1998010779A1 (fr) | 1996-09-13 | 1998-03-19 | New York University | Methode pour traiter des maladies parasitaires avec des inhibiteurs de proteasome |
CA2268391A1 (fr) | 1996-10-18 | 1998-04-30 | Vertex Pharmaceuticals Incorporated | Inhibiteurs de serines proteases, notamment de ns3 protease du virus de l'hepatite c |
SI0932617T1 (en) | 1996-10-18 | 2002-06-30 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
US5874418A (en) | 1997-05-05 | 1999-02-23 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use |
US6046177A (en) | 1997-05-05 | 2000-04-04 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
US6133248A (en) | 1997-06-13 | 2000-10-17 | Cydex, Inc. | Polar drug of prodrug compositions with extended shelf-life storage and a method of making thereof |
US6133308A (en) | 1997-08-15 | 2000-10-17 | Millennium Pharmaceuticals, Inc. | Synthesis of clasto-lactacystin beta-lactone and analogs thereof |
US6100282A (en) * | 1998-01-02 | 2000-08-08 | Hoffman-La Roche Inc. | Thiazole derivatives |
US6075150A (en) | 1998-01-26 | 2000-06-13 | Cv Therapeutics, Inc. | α-ketoamide inhibitors of 20S proteasome |
US6099851A (en) | 1998-06-02 | 2000-08-08 | Weisman; Kenneth M. | Therapeutic uses of leuprolide acetate |
US6462019B1 (en) | 1998-07-10 | 2002-10-08 | Osteoscreen, Inc. | Inhibitors of proteasomal activity and production for stimulating bone growth |
US6838436B1 (en) | 1998-07-10 | 2005-01-04 | Osteoscreen Inc. | Inhibitors of proteasomal activity for stimulating bone growth |
US6902721B1 (en) | 1998-07-10 | 2005-06-07 | Osteoscreen, Inc. | Inhibitors of proteasomal activity for stimulating bone growth |
US6204257B1 (en) | 1998-08-07 | 2001-03-20 | Universtiy Of Kansas | Water soluble prodrugs of hindered alcohols |
EP1123412B1 (fr) | 1998-10-20 | 2004-10-06 | Millennium Pharmaceuticals, Inc. | Procede de controle de l'action medicamenteuse de l'inhibiteur de proteasome |
US6492333B1 (en) | 1999-04-09 | 2002-12-10 | Osteoscreen, Inc. | Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors |
US6831099B1 (en) | 1999-05-12 | 2004-12-14 | Yale University | Enzyme inhibition |
US6114365A (en) * | 1999-08-12 | 2000-09-05 | Pharmacia & Upjohn S.P.A. | Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents |
EP1477180A1 (fr) | 1999-10-20 | 2004-11-17 | Osteoscreen, Inc. | Inhibiteurs de l'activité de proteasome pour favoriser la croissance osseuse et la pousse des cheveux |
EP1430903A1 (fr) | 2000-10-12 | 2004-06-23 | Viromics Gmbh | Inhibiteurs du proteasome pour le traitement des infections virales |
GB0114185D0 (en) * | 2001-06-12 | 2001-08-01 | Protherics Molecular Design Lt | Compounds |
EP1360189A1 (fr) | 2001-01-25 | 2003-11-12 | Millennium Pharmaceuticals, Inc. | Formulation de composes d'acide boronique |
ES2278049T3 (es) | 2001-05-21 | 2007-08-01 | Alcon, Inc. | Uso de inhibidores de proteasoma para tratar trastornos de ojo seco. |
EP1463719A2 (fr) | 2002-01-08 | 2004-10-06 | Eisai Co., Ltd | Analogues d'eponemycine et d'epoxomicine et leurs utilisations |
US20040116329A1 (en) | 2002-01-29 | 2004-06-17 | Epstein Stephen E. | Inhibition of proteasomes to prevent restenosis |
EP1496916A2 (fr) | 2002-04-09 | 2005-01-19 | Greenville Hospital System | Activite de modulation de metastase d'oligosaccharides hautement sulfates |
US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
US20030224469A1 (en) | 2002-06-03 | 2003-12-04 | Buchholz Tonia J. | Methods and kits for assays utilizing fluorescence polarization |
WO2003101481A1 (fr) | 2002-06-03 | 2003-12-11 | Als Therapy Development Foundation | Traitement de maladies neurodegeneratives utilisant des modulateurs de proteasomes |
WO2004010937A2 (fr) | 2002-07-26 | 2004-02-05 | Advanced Research & Technology Institute At Indiana University | Methode de traitement du cancer |
US7189740B2 (en) | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
TW200418791A (en) | 2003-01-23 | 2004-10-01 | Bristol Myers Squibb Co | Pharmaceutical compositions for inhibiting proteasome |
PE20150676A1 (es) | 2003-04-08 | 2015-05-17 | Novartis Ag | Composicion farmaceutica que contiene un agonista del receptor s1p y un alcohol de azucar |
US8338180B2 (en) | 2003-06-10 | 2012-12-25 | The J. David Gladstone Institutes | Methods for treating lentivirus infections |
US7012063B2 (en) | 2003-06-13 | 2006-03-14 | Children's Medical Center Corporation | Reducing axon degeneration with proteasome inhibitors |
CN1976679B (zh) | 2003-12-31 | 2011-08-31 | 锡德克斯药物公司 | 含有磺基烷基醚环糊精以及皮质甾类的吸入制剂 |
GB0400804D0 (en) | 2004-01-14 | 2004-02-18 | Innoscience Technology Bv | Pharmaceutical compositions |
US20050228031A1 (en) * | 2004-04-13 | 2005-10-13 | Bilodeau Mark T | Tyrosine kinase inhibitors |
US8198270B2 (en) | 2004-04-15 | 2012-06-12 | Onyx Therapeutics, Inc. | Compounds for proteasome enzyme inhibition |
CN103554222A (zh) | 2004-04-15 | 2014-02-05 | 欧尼斯治疗公司 | 用于抑制蛋白酶体酶的化合物 |
US7232818B2 (en) | 2004-04-15 | 2007-06-19 | Proteolix, Inc. | Compounds for enzyme inhibition |
AU2005243140A1 (en) | 2004-05-10 | 2005-11-24 | Proteolix, Inc. | Synthesis of amino acid keto-epoxides |
JP5108509B2 (ja) | 2004-05-10 | 2012-12-26 | プロテオリックス, インコーポレイテッド | 酵素阻害のための化合物 |
CN101044157B (zh) * | 2004-08-06 | 2011-07-13 | 普罗特奥里克斯公司 | 用于抑制蛋白酶体的化合物 |
EP2100899A3 (fr) | 2004-10-20 | 2009-09-30 | Proteolix, Inc. | Composés pour inhibition d'enzyme |
EP2260835B1 (fr) | 2004-12-07 | 2013-03-06 | Onyx Therapeutics, Inc. | Composition destinée a inhiber le proteasome |
US7468383B2 (en) | 2005-02-11 | 2008-12-23 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
WO2006099261A2 (fr) | 2005-03-11 | 2006-09-21 | The University Of North Carolina At Chapel Hill | Inhibiteurs puissants et spécifiques d'immunoprotéasomes |
ATE553198T1 (de) | 2005-04-15 | 2012-04-15 | Geron Corp | Behandlung von krebs durch die kombinierte hemmung der proteasom- und telomeraseaktivitäten |
GT200600350A (es) | 2005-08-09 | 2007-03-28 | Formulaciones líquidas | |
NZ595196A (en) | 2005-11-09 | 2013-03-28 | Proteolix Inc | Peptide-based compounds for enzyme inhibition |
AR057227A1 (es) | 2005-12-09 | 2007-11-21 | Centocor Inc | Metodo para usar antagonistas de il6 con inhibidores del proteasoma |
US20070207950A1 (en) | 2005-12-21 | 2007-09-06 | Duke University | Methods and compositions for regulating HDAC6 activity |
WO2007122686A1 (fr) | 2006-04-14 | 2007-11-01 | Eisai R & D Management Co., Ltd. | Composes benzimidazole |
DE102006026464A1 (de) | 2006-06-01 | 2007-12-06 | Virologik Gmbh Innovationszentrum Medizintechnik Und Pharma | Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus |
PL2041158T3 (pl) | 2006-06-19 | 2013-08-30 | Onyx Therapeutics Inc | Peptydowe epoksyketony do hamowania proteasomu |
WO2008033807A2 (fr) | 2006-09-13 | 2008-03-20 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Combinaisons synergiques d'oxydants mitochondriaux antinéoplasiques se liant au thiol et d'inhibiteurs du protéasome antinéoplasiques pour le traitement du cancer |
US8601054B2 (en) * | 2006-12-07 | 2013-12-03 | International Business Machines Corporation | Project-related communications |
WO2008091620A2 (fr) | 2007-01-23 | 2008-07-31 | Gloucester Pharmaceuticals, Inc. | Polythérapie |
WO2008140782A2 (fr) * | 2007-05-10 | 2008-11-20 | Proteolix, Inc. | Composés d'inhibition enzymatique |
WO2009020448A1 (fr) | 2007-08-06 | 2009-02-12 | Millennium Pharmaceuticals, Inc. | Inhibiteurs de protéasomes |
US7442830B1 (en) | 2007-08-06 | 2008-10-28 | Millenium Pharmaceuticals, Inc. | Proteasome inhibitors |
PL2207791T5 (pl) * | 2007-10-04 | 2020-07-27 | Onyx Therapeutics, Inc. | Krystaliczne peptydo- epoksy ketonowe inhibitory proteazy i synteza keto-epoksydów Aminokwasowych |
US7838673B2 (en) | 2007-10-16 | 2010-11-23 | Millennium Pharmaceuticals, Inc. | Proteasome inhibitors |
JP5600595B2 (ja) | 2007-10-16 | 2014-10-01 | ミレニアム ファーマシューティカルズ, インコーポレイテッド | プロテアソーム阻害剤 |
US20090131367A1 (en) | 2007-11-19 | 2009-05-21 | The Regents Of The University Of Colorado | Combinations of HDAC Inhibitors and Proteasome Inhibitors |
EP2730579A1 (fr) | 2008-06-17 | 2014-05-14 | Millennium Pharmaceuticals, Inc. | Composés de borates esters et compositions pharmaceutiques contenant des composés |
AR075090A1 (es) | 2008-09-29 | 2011-03-09 | Millennium Pharm Inc | Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden. |
AP2011005690A0 (en) | 2008-10-21 | 2011-06-30 | Onyx Therapeutics Inc | Combination therapy with peptide epoxyketones. |
TWI504598B (zh) | 2009-03-20 | 2015-10-21 | Onyx Therapeutics Inc | 結晶性三肽環氧酮蛋白酶抑制劑 |
CN101928329B (zh) | 2009-06-19 | 2013-07-17 | 北京大学 | 三肽硼酸(酯)类化合物、其制备方法和应用 |
JP5919196B2 (ja) | 2009-11-13 | 2016-05-18 | オニキス セラピューティクス, インク.Onyx Therapeutics, Inc. | 転移抑制のためのペプチドエポキシケトンの使用 |
BR112012022060A2 (pt) | 2010-03-01 | 2018-05-08 | Onyx Therapeutics Inc | composto para a inibição de imunoproteassoma |
JP5933523B2 (ja) | 2010-03-31 | 2016-06-08 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | 1−アミノ−2−シクロプロピルエチルボロン酸の誘導体 |
NZ602872A (en) | 2010-04-07 | 2014-05-30 | Onyx Therapeutics Inc | Crystalline peptide epoxyketone immunoproteasome inhibitor |
-
2010
- 2010-03-19 TW TW099108136A patent/TWI504598B/zh not_active IP Right Cessation
- 2010-03-19 AR ARP100100894A patent/AR075899A1/es unknown
- 2010-03-20 SA SA110310221A patent/SA110310221B1/ar unknown
- 2010-03-20 SA SA114350283A patent/SA114350283B1/ar unknown
- 2010-03-22 NZ NZ595847A patent/NZ595847A/en not_active IP Right Cessation
- 2010-03-22 BR BRPI1009369A patent/BRPI1009369A2/pt not_active Application Discontinuation
- 2010-03-22 ES ES10754225.0T patent/ES2527619T3/es active Active
- 2010-03-22 MX MX2011009777A patent/MX2011009777A/es active IP Right Grant
- 2010-03-22 GE GEAP201012421A patent/GEP20156392B/en unknown
- 2010-03-22 AU AU2010226410A patent/AU2010226410B2/en not_active Ceased
- 2010-03-22 PE PE2011001673A patent/PE20120645A1/es active IP Right Grant
- 2010-03-22 ME MEP-2011-164A patent/ME01277B/me unknown
- 2010-03-22 PL PL14178725T patent/PL2813241T3/pl unknown
- 2010-03-22 US US13/257,887 patent/US8604215B2/en not_active Expired - Fee Related
- 2010-03-22 SI SI201031354A patent/SI2813241T1/sl unknown
- 2010-03-22 SG SG2014011373A patent/SG2014011373A/en unknown
- 2010-03-22 PT PT141787259T patent/PT2813241T/pt unknown
- 2010-03-22 ES ES14178725.9T patent/ES2614557T3/es active Active
- 2010-03-22 CA CA2755971A patent/CA2755971C/fr not_active Expired - Fee Related
- 2010-03-22 MX MX2013012107A patent/MX343562B/es unknown
- 2010-03-22 KR KR1020117022814A patent/KR101729344B1/ko active IP Right Grant
- 2010-03-22 NZ NZ61843210A patent/NZ618432A/en not_active IP Right Cessation
- 2010-03-22 PT PT107542250T patent/PT2408758E/pt unknown
- 2010-03-22 DK DK10754225.0T patent/DK2408758T3/da active
- 2010-03-22 SG SG2011067204A patent/SG174446A1/en unknown
- 2010-03-22 MY MYPI2011004414A patent/MY156522A/en unknown
- 2010-03-22 WO PCT/US2010/028126 patent/WO2010108172A1/fr active Application Filing
- 2010-03-22 RS RS20161122A patent/RS55431B1/sr unknown
- 2010-03-22 HU HUE14178725A patent/HUE032430T2/en unknown
- 2010-03-22 JP JP2012501028A patent/JP5723357B2/ja active Active
- 2010-03-22 SI SI201030833T patent/SI2408758T1/sl unknown
- 2010-03-22 MA MA34254A patent/MA33197B1/fr unknown
- 2010-03-22 PL PL10754225T patent/PL2408758T3/pl unknown
- 2010-03-22 LT LTEP14178725.9T patent/LT2813241T/lt unknown
- 2010-03-22 US US12/728,547 patent/US20100240903A1/en not_active Abandoned
- 2010-03-22 EA EA201300860A patent/EA024672B1/ru not_active IP Right Cessation
- 2010-03-22 EP EP14178725.9A patent/EP2813241B1/fr active Active
- 2010-03-22 CN CN201080021879.8A patent/CN102428075B/zh not_active Expired - Fee Related
- 2010-03-22 EP EP10754225.0A patent/EP2408758B1/fr active Active
- 2010-03-22 EA EA201171151A patent/EA020973B1/ru not_active IP Right Cessation
- 2010-03-22 RS RS20150015A patent/RS53746B1/en unknown
- 2010-03-22 DK DK14178725.9T patent/DK2813241T3/en active
- 2010-03-22 AP AP2013007137A patent/AP3513A/xx active
-
2011
- 2011-09-15 IL IL215174A patent/IL215174A/en not_active IP Right Cessation
- 2011-09-16 DO DO2011000286A patent/DOP2011000286A/es unknown
- 2011-09-16 CO CO11120506A patent/CO6430433A2/es not_active Application Discontinuation
- 2011-09-19 TN TN2011000470A patent/TN2011000470A1/fr unknown
- 2011-09-19 CR CR20110491A patent/CR20110491A/es unknown
- 2011-09-19 ZA ZA2011/06826A patent/ZA201106826B/en unknown
- 2011-09-20 CU CU20110176A patent/CU20110176A7/es unknown
- 2011-09-20 CL CL2011002326A patent/CL2011002326A1/es unknown
- 2011-09-20 NI NI201100170A patent/NI201100170A/es unknown
- 2011-09-20 US US13/237,655 patent/US8822512B2/en not_active Expired - Fee Related
- 2011-09-20 HN HN2011002459A patent/HN2011002459A/es unknown
- 2011-09-20 EC EC2011011341A patent/ECSP11011341A/es unknown
-
2012
- 2012-03-15 HK HK12102641.5A patent/HK1162476A1/xx not_active IP Right Cessation
-
2013
- 2013-09-24 US US14/035,644 patent/US9051353B2/en not_active Expired - Fee Related
-
2015
- 2015-01-08 HR HRP20150014AT patent/HRP20150014T1/hr unknown
- 2015-01-12 SM SM201500009T patent/SMT201500009B/xx unknown
- 2015-03-05 US US14/639,603 patent/US9403868B2/en not_active Expired - Fee Related
- 2015-06-16 HK HK15105658.5A patent/HK1204952A1/xx not_active IP Right Cessation
-
2016
- 2016-03-11 ZA ZA2016/01686A patent/ZA201601686B/en unknown
- 2016-12-06 HR HRP20161654TT patent/HRP20161654T1/hr unknown
- 2016-12-16 CY CY20161101307T patent/CY1118359T1/el unknown
-
2017
- 2017-01-30 SM SM201700068T patent/SMT201700068B/it unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA33197B1 (fr) | Inhibiteurs de tripeptide époxy cétone protéases cristallines | |
UA97502C2 (ru) | Кристаллическая твердая основа разагилина | |
TN2009000446A1 (en) | P70 s6 kinase inhibitors | |
WO2011032169A3 (fr) | Compositions et formulations pharmaceutiques comprenant des inhibiteurs du domaine d'homologie à la pleckstrine et leurs méthodes d'utilisation | |
MA33803B1 (fr) | Inhibiteur de bromodomaine de benzodiazépine | |
MX346608B (es) | Compuestos de isoindol 5-sustituidos. | |
GEP20135964B (en) | Inhibitors of beta-secretase | |
MX2009000884A (es) | Derivados de piridizinona. | |
TW201713640A (en) | Bruton's tyrosine kinase inhibitors | |
UA103930C2 (ru) | Соединения и композиция для лечения паразитарных болезней | |
MX2012007375A (es) | 3-ceto-n-propargil 1-aminoindano. | |
MA33208B1 (fr) | Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci | |
NO20081554L (no) | Isoindollmidforbindelser og sammensetninger omfattende samme, og anvendelse derav | |
MY162157A (en) | Substituted indole mcl-1 inhibitors | |
MX2012002366A (es) | Agonistas novedosos de receptores beta 3 andrenergicos derivados de pirrolidina. | |
MX2010000593A (es) | Aumentador del vigor de una planta. | |
GEP20156242B (en) | 2-arylimidazole derivatives as pde10a enzyme inhibitors | |
MX2012004780A (es) | Inhibidores de akt. | |
GEP20135806B (en) | Lactams as beta secretase inhibitors | |
EA201101118A1 (ru) | Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина | |
WO2011009039A3 (fr) | Produit pharmaceutique pour administration par voie orale comprenant mgbg et procédés de traitement de maladie | |
WO2012075015A3 (fr) | Compositions pharmaceutiques orales de métronidazole | |
MX339619B (es) | Formulaciones, sales y polimorfos de transnorsertralina y usos de los mismos. | |
TW200638932A (en) | CCI-779 polymorph and use thereof | |
WO2012021788A3 (fr) | Inhibiteurs dipeptidiques de la calpaïne |